Skip to main content

A Residual Pigmentary Lesion After Melanoma Surgery

  • Chapter
  • First Online:
Clinical Cases in Melanoma

Part of the book series: Clinical Cases in Dermatology ((CLIDADE))

  • 286 Accesses

Abstract

A 90-years-old patient underwent a surgery for a nodule on the vertex with the outcome of non-ulcered nodular melanoma, which was dermis-infiltrating with 2.9 mm Breslow. Associated to the nodular component there was an extended pigmented lesion, as in the Picture 17.1.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 29.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 39.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tio D, Van der Woude J, Prinsens CAC, et al. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization treatment of treatment schedule and outcome measures. J Eur Acad Dermatol Venereol. 2017;31(4):616–24.

    Article  CAS  Google Scholar 

  2. Hamilko de Barros M, Conforti C, Giuffrida R, et al. Clinical usefulness of dermoscopy in the management of lentigo maligna melanoma treated with topical imiquimod: a case report. Dermatol Ther. 2019;32:e13048.

    Article  Google Scholar 

  3. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. 2010;46:270–83.

    Article  Google Scholar 

  4. Tsay C, Kim S, Norwich-Cavanaugh A, et al. An algorithm for the management of residual head and neck melanoma in situ using topical imiquimod. Ann Plast Surg. 2019;82:S199–201.

    Article  CAS  Google Scholar 

  5. Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiqui-mod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62:582–90.

    Article  CAS  Google Scholar 

  6. Swanson N, Smith CC, Kaur M, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Drugs Dermatol. 2014;13:166–9.

    CAS  PubMed  Google Scholar 

  7. Tio D, Van Montfrans C, Ruijter CGH, Hoekzema R, Bekkenk MW. Effectiveness of 5%. Topical imiquimod for lentigo maligna treatment. Acta Derm Venereol. 2019;99:884–8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2020 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rovesti, M., Feliciani, C., Zucchi, A., Lotti, T., Satolli, F. (2020). A Residual Pigmentary Lesion After Melanoma Surgery. In: Lotti, T., Tirant, M., Wollina, U. (eds) Clinical Cases in Melanoma. Clinical Cases in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-030-50820-3_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-50820-3_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-50819-7

  • Online ISBN: 978-3-030-50820-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics